Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. [electronic resource]
Producer: 20060522Description: 242-55 p. digitalISSN:- 0361-8609
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Benzamides
- Bone Marrow Cells -- enzymology
- Caspase 3
- Caspase Inhibitors
- Caspases -- metabolism
- Celecoxib
- Cyclin D1 -- metabolism
- Cyclin E -- metabolism
- Cyclin-Dependent Kinase Inhibitor p16 -- metabolism
- Cyclin-Dependent Kinase Inhibitor p27
- Cyclooxygenase 2 -- biosynthesis
- Cyclooxygenase Inhibitors -- pharmacology
- Dose-Response Relationship, Drug
- Down-Regulation -- drug effects
- Drug Synergism
- Enzyme Activation -- drug effects
- Enzyme Inhibitors -- pharmacology
- G1 Phase -- drug effects
- Gene Expression Regulation, Enzymologic -- drug effects
- Gene Expression Regulation, Leukemic -- drug effects
- Humans
- Hydroxyurea -- pharmacology
- Imatinib Mesylate
- Interleukin-1 -- pharmacology
- Intracellular Signaling Peptides and Proteins -- metabolism
- K562 Cells
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Membrane Proteins -- antagonists & inhibitors
- Piperazines -- pharmacology
- Pyrazoles -- pharmacology
- Pyrimidines -- pharmacology
- S Phase -- drug effects
- Sulfonamides -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.